Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy

Canadian Journal of Ophthalmology

Volumn 45, Issue 1, 2010, Pages 71-75

  Stiebel Kalish, Hadas ^a,b   Hammel, Naama ^a,b   Van Everdingen, Judith ^c   Huna Baron, Ruth ^b,d   Lee, Andrew G ^e  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ROTTERDAM EYE HOSPITAL   (Netherlands)

^d SHEBA MEDICAL CENTER   (Israel)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Immune system disease; Immunology; Neuro ophthalmology; Optic neuritis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; OPTIC NEURITIS; RECURRENT DISEASE; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISION;

EID: 76149129763     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-238     Document Type: Article

References (19)

1. Kupersmith MJ, Burde RM, Warren FA, Klingele TG, Frohman LP, Mitnick H. Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatry 1988;51: 1381-6.
2. Dutton JJ, Burde RM, Klingele TG. Autoimmune retrobulbar optic neuritis. Am J Ophthalmol 1982;94:11-7.
3. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003;126: 276-84.
4. Kupersmith MJ, Burde RM,Warren FA, Klingele TG, Frohman LP, Mitnick H. Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatry 1988;51:1381-6.
5. Pérez-Diaz H, Casado JL, Uclés-Sánchez A, Saiz A. Chronic relapsing inflammatory optic neuropathy (CRION) without detection of IgG-NMO antibodies [in Spanish]. Neurologia 2007;22:553-5.
6. Myers TD, Smith JR, Wertheim MS, Egan RA, Shults WT, Rosenbaum JT. Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. Br J Ophthalmol 2004;88:673-80.
7. Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001;85:1220-4.
8. Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 2005;1051:779-86.
9. Frohman L, Turbin R, Bielory L, Wolansky L, Lambert WC, Cook S. Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child. Am J Ophthalmol 2003;136:358-60.
10. Frohman LP, Cook SD, Bielory L. Dysgammaglobulinemia in steroid-dependent optic neuritis: response to gammaglobulin treatment. J Clin Neuroophthalmol 1991;11:241-5.
11. Kurz D, Egan RA, Rosenbaum JT. Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulin. Am J Ophthalmol 2005;140:1132-3.
12. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51:S2-S8.
13. Vani J, Elluru S, Negi VS, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008;7:440-4.
14. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007;2:9-18.
15. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005;14: 802-8.
16. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney - a two-edged sword. Semin Arthritis Rheum 2004;34:593-601.
17. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84.
18. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6: 257-9.
19. Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005;14: 802-8.